Q&A with Vadim Alexandre Head of Research at Northland Capital Partners

Northland Capital Partners Head of Research Vadim Alexandre caught up with DirectorsTalk for an exclusive interview to discuss ImmuPharma PLC (LON:IMM)

 

Q1: Now Vadim, Northland have just been appointed as nominated adviser and sole broker, with immediate effect, to ImmuPharma PLC, what are your thoughts on the company?

A1: So ImmuPharma’s a rare gem on AIM in that it’s a company with a late-state drug development asset, there aren’t that many and what we mean by that is that it has a Phase III asset, a drug that’s Phase III in terms of clinical trial development. Overall, what I see is that ImmuPharma is grossly undervalued, basically a drug with this stage of asset development usually it is significantly more valued than where it is, currently ImmuPharma’s market cap is just over £50 million, US peers in that space are in the hundreds of millions. So, there’s a rare opportunity here to get into a relatively low risk asset at a good price.

 

Q2: What are ImmuPharma’s prospects for the next few years?

A2: In terms of this trial, so this is their lead asset which is a drug called Lupuzor, it’s for the treatment of lupus, that trial is ongoing, in fact they just announced, at the end of the last year, that enrolment is complete for that trial. So not only are they in Phase III trials for that treatment but the trial itself is fully enrolled which means that we can expect a read-out from that trial before the year-end of this year-end and that a positive read-out in that trial would be a substantial achievement for the company. We would expect that to have a major re-rating in the share price especially given, as I was saying previously, that the shares I believe are grossly undervalued. Finally, they have other assets in other programmes, they have an oncology programme which is Phase II ready and they have some pre-clinical assets as well, all of which we hope to see some news flow from but the key here really is the read-out this year on that Phase III trial and again, enrolment complete sets a timeline which we can almost be sure that that read-out should happen sometime this year.

 

Q3: Who are ImmuPharma’s closest peers in the UK?

A3: There is another company called Motif Bio PLC (LON:MTFB), it’s not a peer in terms of the same asset class so it’s in a different area, it’s an antibiotic, however it’s a Phase III as well, and that company also, right now, is conducting two Phase III trials which are supposed to read-out in the next quarter, like I was saying, the key there is that they’re late-stage companies. More importantly is, in terms of the exact area in which ImmuPharma is in, there’s a drug called Benlysta which is a GlaxoSmithKline plc (GSK) drug, you were talking about peers well it’s interesting to know that Glaxo bought that drug or bought in the rights to that drug from another company called Human Genome Sciences (NASDAQ:HGSI). They bought a 50% stake in it, well the residual 50% stake that they didn’t have they were jointly developing this drug Benlysta for lupus, for $3.5 billion or something like that, just over $3 billion so it gives you an idea of the potential valuation of a successful drug, a new successful drug like ImmuPharma’s Lupuzor, how much it can command in terms of interest from a large cap pharma.

 

Click to view all articles for the EPIC: , , ,
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Immupharma Plc

    More articles like this

    Edenville Energy Plc

    Edenville Energy much improved performance at Rukwa

    Edenville Energy Plc (LON:EDL) has provided a production update regarding its Rukwa Coal Project. A total of 594 tonnes of coal were washed at Rukwa in March 2023. Of this, 512.5 tonnes of coal were washed from

    Eden Research

    Edenville Energy updates on Rukwa Coal Project

    Edenville Energy Plc (LON:EDL) has provided an update on operations at its Rukwa Coal Project in Tanzania. Following the recommencement of production at Rukwa, as announced on 11 October 2022, the Company is pleased to report

    Edenville Energy Plc

    Edenville Energy production recommenced at Rukwa Coal Project

    Edenville Energy Plc (LON:EDL) has provided an update on operations at its Rukwa Coal Project in Tanzania. Highlights –      Production recommenced at Rukwa at an initial 4,000 tonnes per month of washed coal –      Completed overhaul of wash plant

    Edenville Energy Plc

    Edenville Energy to expand operations at Rukwa

    Edenville Energy plc (LON:EDL) has announced that, following a period of previously announced disappointing performance at Rukwa Coal Project, a new experienced on-site management team has been mobilised to run its mine at Rukwa in Western

    Edenville Energy Plc

    Edenville Energy signs new coal mining contract with Nextgen

    Edenville Energy Plc (LON:EDL) has announced its subsidiary Edenville International (Tanzania) Limited has entered into a contract with Nextgen Coalmine Limited for the operation of the Company’s Rukwa Coal Project in Tanzania..  The Agreement is for

    Edenville Energy Plc

    Edenville Energy appoint Tavira Securities as broker

    Edenville Energy Plc (LON:EDL) has announced the appointment of Tavira Securities Limited as broker to the Company. Tavira has recruited senior personnel that managed the Edenville relationship for the Company’s former broker, Brandon Hill Capital Limited, including Oliver Stansfield